Replies to post #72887 on Biotech Values

[DewDiligence]

IDIX – I was hoping for a better upfront somewhere between 30-40M…

The $34M up-front they got is in the middle of your range.

…so the company would have more cash cushion till next year.

IDIX now has about $75M of cash with no debt. Moreover, there’s a decent chance of bringing in more cash in 2009 from HCV deals.

In short, IDIX’s balance sheet is pretty good; in contrast to many small biotech companies, movements in IDIX’s share price are apt to reflect the company’s clinical progress and buyout vig rather than its financial condition.

[DewDiligence]

IDIX – Caris & Co. started coverage yesterday with a Buy rating and a $17 target:

http://www.gainerstoday.com/UserRecommendations.aspx?StockID=&UserID=2965&SortField=StockID&SortDirection=ASC&Year=0&PageNumber=3

Analyst ratings are BS, of course; still, it’s nice to know that someone besides me thinks the IDX899 deal with GSK is a good one.